Sign in Create account

Indoco Remedies Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: INDOCO BSE: 532612
₹261.67
▼ -7.48 (-2.78%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
46/100
Moderate
Valuation
72/100
Undervalued
Momentum
85/100
Bullish

QVM read Cheap and turning up Quality Moderate, Valuation Undervalued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹2,415 Cr
PE (TTM)
23.1
Industry median 36.1 (152 companies)
Price to Book
2.6
PEG (TTM)
0.1
Institutions holding %
18.95%
FII + DII, latest filed period
Piotroski Score
6
Relative return vs Nifty50, qtr %
14.2
Relative return vs Sector, qtr %
10.6
Free Cash Flow
₹45 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
393.42%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
103.80%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
12.68%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-151.12%
as of Dec. 31, 2024
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
4.19%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.13
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
1.11
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
2.26
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
20.13%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
28.36%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
11.63%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-3.81%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
1.02%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-10.59%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 7 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 6)
  • No Debt to equity is below 0.5 (1.11)
  • No Return on equity is 15% or more (-10.6%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

5 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.8%
Low 255.3500 · High 274.8700
1W return
4.2%
Low 244.2000 · High 284.7700
1M return
7.5%
Low 229.0000 · High 287.8000
52W return
-9.8%
Low 162.1900 · High 317.3500
Lifetime High ₹537.8000 (Nov. 10, 2010)
Lifetime Low ₹52.8500 (June 18, 2012)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
258.8
10D
256.1
20D
252.1
50D
243.6
100D
235.6
200D
222.5

Delivery and volume

Day avg. delivery
37.4%
Week avg. delivery
8.8%
Month avg. delivery
9.4%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

263.96
Pivot
First resistance272.58
Second resistance283.48
Third resistance292.10
First support253.06
Second support244.44
Third support233.54
Day RSI55.9
Day MFI94.3
Day MACD5.30
Day MACD signal5.02

Beta

1M2.58
3M0.80
1Y0.95
3Y0.86

Price change analysis

↑ 7.5%
Over 1 Month
LowHigh
229.00287.80
↑ 10.6%
Over 3 Months
LowHigh
214.06287.80
↑ 39.9%
Over 6 Months
LowHigh
180.30287.80
↓ -9.8%
Over 1 Year
LowHigh
162.19317.35
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 23.1 (own history: 21.1–55.6)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹409 Cr
Net profit (June 30, 2026)
₹82 Cr
Basic EPS (June 30, 2026)
₹8.9200

Ranks #74 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter58.86%
  • Mutual funds17.16%
  • FII/FPI1.27%
  • Other DII0.52%
  • Public22.05%

Largest holders

NameCategoryShares %Shares
SPA HOLDINGS PVT LTDPromoter19.8600%18335000
SHANTERI INVESTMENT PVT LTDPromoter17.1800%15858805
KARE FAMILY PRIVATE TRUSTPromoter14.1900%13097055
NIPPON LIFE INDIA TRUSTEE LTD A/C NIPPON INDIA SMALL CAP FUNDPublic4.8000%4429483
QUANT MUTUAL FUND QUANT SMALL CAP FUNDPublic4.5500%4199230

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 58.86% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.94% to 1.27% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 17.54% to 17.16% in Jun 2026 qtr

5 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 65 insider trades, 101 SAST, 2 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
31 Dec 2025 KARE FAMILY PRIVATE TRUST Promoter Buy 0 ₹0
31 Dec 2025 ARUNA SURESH KARE Promoter Sell 0 ₹0
28 Nov 2025 ADITI M PANANDIKAR Promoter Sell 0 ₹0
28 Nov 2025 MADHURA SURESH KARE Promoter Sell 0 ₹0
28 Nov 2025 SURESH GOVIND KARE Promoter Sell 0 ₹0
28 Nov 2025 KARE FAMILY PRIVATE TRUST Promoter Buy 0 ₹0
28 Nov 2025 ARUNA SURESH KARE Promoter Buy 0 ₹0
28 Nov 2025 ARUNA SURESH KARE Promoter Sell 0 ₹0
8 Aug 2025 ADITI M. PANANDIKAR Promoter Buy 0 ₹0
8 Aug 2025 MADHURA SURESH KARE Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 63 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
29 Sep 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 691,564 273.2700 NSE
29 Sep 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 691,564 273.1400 NSE
29 Sep 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Buy 969,889 273.0400 NSE
29 Sep 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Sell 969,889 273.4500 NSE
29 Sep 2026 JUNOMONETA FINSOL PRIVATE LIMITED Bulk Sell 664,724 274.8600 NSE
29 Sep 2026 JUNOMONETA FINSOL PRIVATE LIMITED Bulk Buy 663,827 274.6000 NSE
29 Sep 2026 BLITZQUANT RESEARCH LLP Bulk Buy 464,497 277.7400 NSE
29 Sep 2026 BLITZQUANT RESEARCH LLP Bulk Sell 464,497 277.8800 NSE
29 Sep 2026 BLITZQUANT RESEARCH LLP Bulk Sell 464,497 277.8800 NSE
29 Sep 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Sell 969,889 273.4500 NSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
28 Jul 2026 Financial Results Yes
3 Feb 2026 Financial Results Yes
6 Nov 2025 Financial Results Yes
24 Jul 2025 Financial Results Yes
22 May 2025 Financial Results/Dividend Yes

Corporate Announcements

All 10 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 Company Update Indoco Remedies Ltd - 532612 - Intimation To Shareholders Holding Shares In Physical Mode Regarding Mandatory Furnishing Of PAN, KYC And Bank Details As Per SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 Dated February 6, 2026
28 Sep 2026 Insider Trading / SAST Indoco Remedies Ltd - 532612 - Closure of Trading Window
28 Sep 2026 Company Update Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Acquisition
18 Sep 2026 AGM/EGM Indoco Remedies Ltd - 532612 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
18 Sep 2026 Company Update Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Acquisition
10 Sep 2026 Company Update Indoco Remedies Ltd - 532612 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations,2015
10 Sep 2026 Insider Trading / SAST Indoco Remedies Ltd - 532612 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
5 Sep 2026 Company Update Indoco Remedies Ltd - 532612 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations,2015
3 Sep 2026 Insider Trading / SAST Indoco Remedies Ltd - 532612 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
1 Sep 2026 Insider Trading / SAST Indoco Remedies Ltd - 532612 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (20.1%)

Weaknesses

  • Low Return on Equity (-10.6%)
  • High financial leverage (Debt/Equity 1.11)
  • Declining profit YoY (-151.1%)

Opportunities

  • PEG below 1 (0.08) -- earnings growth outpacing its own valuation

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Indoco Remedies Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.